Zip code for 4d molecular therapeutics12/3/2023 ![]() Cash and cash equivalents of approximately $277M as of Dec 31, 2020Įmeryville, CA March 25, 2021 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power ofĭirected evolution for targeted gene therapies, announced financial results for the year ended December 31, 2020 and provided operational highlights. Initiate clinical trial in the second half of 2021 ![]() Intravitreal product candidate 4D-150 for the treatment of wet AMD Of choroideremia, completed dose escalation portion of Phase 1/2 clinical Intravitreal product candidates, 4D-125 for the treatment of XLRP and 4D-110 for the treatment First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease Securities and Exchange Commission made by 4DMT, whether made before or after the date hereof, regardless of any general incorporation language in such filing.ĤD Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 The information contained herein and in the accompanyingĮxhibit shall not be incorporated by reference into any filing with the U.S. Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this report, including the exhibit hereto, shall not be deemed to be filed for purposes of Press Release, dated March 25, 2021, titled ∴D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights AĬopy of 4DMTs press release, titled ∴D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights, is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto. (∴DMT) announced its audited financial results for the year ended December 31, 2020. On March 25, 2021, 4D Molecular Therapeutics, Inc. Results of Operations and Financial Condition. Growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act ofġ933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Securities registered pursuant to Section 12(b) of the Act:Ĭommon Stock, $0.0001 par value per share Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) The registrant under any of the following provisions: Registrants telephone number, including area code: (510) 505-2680Ĭheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of ![]() (Address of principal executive offices, including Zip Code) (Exact name of registrant as specified in its charter) Date of Report (Date of earliest event reported): March 25, 2021
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |